Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR known ✓ | Q92847 | 1/20 | 0.38 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.61 |
| ▸ | GNPAT | O15228 | 1/20 | 0.39 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.38 |
| ▸ | ECE1 | P42892 | 1/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.37 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.37 |
| ▸ | ERAP2 | Q6P179 | 3/20 | 0.36 |
| ▸ | LNPEP | Q9UIQ6 | 3/20 | 0.36 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL27535790 | 1.00 | SLC15A2 (0.61) | SLC15A2GNPATGHSRSLC6A5ECE1 | |
| SCHEMBL8832939 | 0.97 | SLC15A2 (0.64) | SLC15A2GNPATGHSRSLC6A5ECE1 | |
| SCHEMBL5598418 | 0.97 | SLC15A2 (0.64) | SLC15A2GNPATGHSRSLC6A5ECE1 | |
| SCHEMBL259084 | 0.97 | SLC15A2 (0.64) | SLC15A2GNPATGHSRSLC6A5ECE1 | |
| SCHEMBL259085 | 0.97 | SLC15A2 (0.64) | SLC15A2GNPATGHSRSLC6A5ECE1 | |
| SCHEMBL10595108 | 0.97 | SLC15A2 (0.64) | SLC15A2GNPATGHSRSLC6A5ECE1 | |
| SCHEMBL4589903 | 0.96 | SLC15A2 (0.63) | SLC15A2GNPATGHSRSLC6A5ECE1 | |
| SCHEMBL2817828 | 0.96 | SLC15A2 (0.63) | SLC15A2GNPATGHSRSLC6A5ECE1 | |
| SCHEMBL29473319 | 0.96 | SLC15A2 (0.63) | SLC15A2GNPATGHSRSLC6A5ECE1 | |
| SCHEMBL4589314 | 0.96 | SLC15A2 (0.63) | SLC15A2GNPATGHSRSLC6A5ECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4608341-A | IMMUNOASSAY | INTERTHYR RESEARCH FOUNDATION, INC. (US) | 1986-08-26 | — | — | US | claimed |
| US-11478523-B2 | Oriental medicine composition effective for thyroid hormone level normalization | KIM, HYONG JUN (KR) | 2022-10-25 | — | — | US | disclosed |
| US-20160220536-A1 | USE OF PHENYLMETHIMAZOLES, METHIMAZOLE DERIVATIVES, AND TAUTOMERIC CYCLIC THIONES FOR THE TREATMENT OF AUTOIMMUNE/INFLAMMATORY DISEASES ASSOCIATED WITH TOLL-LIKE RECEPTOR OVEREXPRESSION | UNIV OHIO (US) | 2016-08-04 | — | — | US | disclosed |
| US-9326972-B2 | Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression | OHIO UNIVERSITY (US) | 2016-05-03 | — | — | US | disclosed |
| US-20120238610-A1 | Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression | OHIO UNIVERSITY | 2012-09-20 | — | — | US | disclosed |
| US-8202692-B2 | Expression profile of thyroid cancer | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-06-19 | — | — | US | disclosed |
| EP-2399578-A1 | Methods and compositions for the treatment of autoimmune and inflammatory diseases associated with toll-like receptors | The Interthyr Corporation (US) | 2011-12-28 | — | — | EP | disclosed |
| US-20100055704-A1 | EXPRESSION PROFILE OF THYROID CANCER | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100004304-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MALIGNANT MELANOMA, BREAST, PROSTATE, COLON, PAPILLARY THYROID AND PANCREATIC CANCER | OHIO UNIVERSITY | 2010-01-07 | — | — | US | disclosed |
| US-7598052-B2 | Expression profile of thyroid cancer | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-10-06 | — | — | US | disclosed |
| US-5871950-A | SUPPRESSION OF MAJOR HISTOCOMPATIBILITY COMPLEX TO CONTROL IMMUNE RESPONSE OF CELLS | SINGER DINAH S (US) | 1999-02-16 | — | — | US | disclosed |
| EP-0880701-A1 | METHODS OF ASSESSING MHC CLASS I EXPRESSION AND PROTEINS CAPABLE OF MODULATING CLASS I EXPRESSION | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-12-02 | — | — | EP | disclosed |
| WO-1997007404-A1 | METHODS OF ASSESSING MHC CLASS I EXPRESSION AND PROTEINS CAPABLE OF MODULATING CLASS I EXPRESSION | THE GOVERMENT OF THE UNITED STATES OF AMERICA reprsented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-02-27 | — | — | WO | disclosed |
| US-5556754-A | MAJOR HISTOCOMPATIBILITY COMPLEX, TREATMENT OF AUTOIMMUNE DISEASES | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-09-17 | — | — | US | disclosed |
| EP-0702554-A1 | USE OF AN MHC CLASS I SUPPRESSOR DRUG FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND TRANSPLANTATION REJECTION | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services (US) | 1996-03-27 | — | — | EP | disclosed |
| WO-1994028897-A2 | USE OF AN MHC CLASS I SUPPRESSOR DRUG FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND TRANSPLANTATION REJECTION | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1994-12-22 | — | — | WO | disclosed |
| US-4609622-A | Clinical determination and/or quantification of thyrotropin and a variety of thyroid stimulatory or inhibitory factors performed in vitro with an improved thyroid cell line, FRTL-5 | INTERTHYR RESEARCH FOUNDATION INC. (US) | 1986-09-02 | — | — | US | disclosed |
| US-4608341-A | IMMUNOASSAY | INTERTHYR RESEARCH FOUNDATION, INC. (US) | 1986-08-26 | — | — | US | disclosed |
| US-4178359-A | Immunoassay method | HOFFMANN-LA ROCHE INC. (US) | 1979-12-11 | — | — | US | disclosed |
| US-4178360-A | Radiolabelled rubella virus and method | HOFFMANN-LA ROCHE INC. (US) | 1979-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238610-A1 | Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression | IRF3, TLR3, TLR4 | GHSR 2105/4885SLC15A2 1774/4885GNPAT 3762/4885 |
| US-20160220536-A1 | USE OF PHENYLMETHIMAZOLES, METHIMAZOLE DERIVATIVES, AND TAUTOMERIC CYCLIC THIONES FOR THE TREATMENT OF AUTOIMMUNE/INFLAMMATORY DISEASES ASSOCIATED WITH TOLL-LIKE RECEPTOR OVEREXPRESSION | IRF3, TLR3, TLR4 | GHSR 2105/4885SLC15A2 1774/4885GNPAT 3762/4885 |
| US-20100004304-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MALIGNANT MELANOMA, BREAST, PROSTATE, COLON, PAPILLARY THYROID AND PANCREATIC CANCER | STAT3, STAT6, TLR3 | GHSR 847/4885SLC15A2 4036/4885GNPAT 3360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.